8-K/AAcquisitions & DispositionsExhibits & Filings

CVS HEALTH Corp 8-K/A Report, Acquisition Completed (Aug 8, 2006)

Filed August 8, 2006For Securities:CVS

Summary

This 8-K/A filing details CVS Corporation's acquisition of approximately 700 standalone drugstores and a distribution center from Albertson's, Inc. for $4.0 billion. The acquisition, completed on June 2, 2006, was financed through commercial paper and a $1.0 billion bridge loan. CVS plans to refinance the commercial paper with longer-term debt and expects to monetize a significant portion of the acquired real estate through sale-leaseback transactions in the fourth quarter of 2006 to help retire the bridge loan. The filing also includes extensive financial information related to the acquired "Standalone Drug Business," including carve-out financial statements and pro forma combined financial information. This provides investors with a view of the acquired business's historical performance and its projected impact on CVS's financial statements post-acquisition. The pro forma information highlights the preliminary nature of the purchase price allocation, indicating potential for future adjustments.

Key Highlights

  • 1CVS acquired approximately 700 standalone drugstores and a distribution center from Albertson's for $4.0 billion on June 2, 2006.
  • 2The acquisition was financed using commercial paper and a $1.0 billion bridge loan, with plans for future refinancing and real estate sale-leaseback transactions.
  • 3The filing provides carve-out financial statements for the acquired Albertson's Standalone Drug Business, showing revenues and direct expenses, as well as net assets acquired.
  • 4Pro forma combined financial statements are presented, illustrating the potential financial impact of the acquisition on CVS.
  • 5The company expects to refinance a portion of commercial paper borrowings with longer-term financing in Q3 2006.
  • 6A substantial portion of the acquired real estate is planned for sale-leaseback transactions in Q4 2006 to aid in retiring the bridge loan.
  • 7The purchase price allocation in the pro forma statements is preliminary and subject to change.

Frequently Asked Questions

This filing serves as an amendment to a previous 8-K, providing detailed financial information related to CVS Corporation's acquisition of the Standalone Drug Business from Albertson's, Inc. It includes carve-out financial statements of the acquired business and pro forma combined financial statements, giving investors a comprehensive view of the transaction's financial implications.

The acquisition was financed through a combination of commercial paper and a $1.0 billion bridge loan. CVS intends to refinance a portion of the commercial paper with longer-term financing in the third quarter of 2006. Additionally, the company plans to sell a significant portion of the acquired real estate through sale-leaseback transactions in the fourth quarter of 2006, with the proceeds intended to be used to retire the bridge loan facility.

The filing includes audited and unaudited carve-out special purpose financial statements for the Albertson's Standalone Drug Business. These statements detail revenues, direct expenses, and net assets acquired as of specific dates. Pro forma combined financial statements are also presented, which merge CVS's historical data with the acquired business's data to show a hypothetical combined financial picture.

No, the filing explicitly states that the purchase price allocation included in the unaudited pro forma combined financial statements is preliminary. This means that the allocation of the purchase price to various assets and liabilities is based on information available at the time of filing and is subject to change, which could have a material impact.